Astrazeneca PLC (NYSE:AZN)‘s stock had its “buy” rating restated by investment analysts at BMO Capital Markets in a research report issued on Tuesday, November 7th. They currently have a $38.00 price objective on the stock. BMO Capital Markets’ price target would indicate a potential upside of 13.57% from the stock’s previous close.
Other research analysts also recently issued reports about the stock. Citigroup Inc. raised shares of Astrazeneca PLC to a “buy” rating in a research report on Wednesday, October 18th. Piper Jaffray Companies reissued a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 9th. BidaskClub downgraded shares of Astrazeneca PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Cowen and Company restated a “hold” rating and issued a $34.00 price objective on shares of Astrazeneca PLC in a research note on Friday, July 28th. Finally, Morgan Stanley cut shares of Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, July 28th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $34.20.
Astrazeneca PLC (NYSE AZN) opened at $33.46 on Tuesday. Astrazeneca PLC has a fifty-two week low of $25.55 and a fifty-two week high of $35.60. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72. The company has a market cap of $83,090.00, a PE ratio of 7.99, a PEG ratio of 3.16 and a beta of 0.79.
Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.55. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 34.02%. The company had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $6 billion. During the same period in the previous year, the firm earned $1.32 EPS. Astrazeneca PLC’s revenue was up 9.4% on a year-over-year basis. analysts anticipate that Astrazeneca PLC will post 1.93 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its position in shares of Astrazeneca PLC by 287,844.0% in the 1st quarter. BlackRock Inc. now owns 6,910,657 shares of the company’s stock valued at $215,198,000 after acquiring an additional 6,908,257 shares during the period. Nuveen Asset Management LLC acquired a new stake in shares of Astrazeneca PLC in the 1st quarter valued at approximately $225,000. Fox Run Management L.L.C. acquired a new stake in shares of Astrazeneca PLC in the 2nd quarter valued at approximately $808,000. Capital One National Association acquired a new stake in shares of Astrazeneca PLC in the 2nd quarter valued at approximately $203,000. Finally, Atria Investments LLC raised its position in shares of Astrazeneca PLC by 0.5% in the 2nd quarter. Atria Investments LLC now owns 24,695 shares of the company’s stock valued at $842,000 after acquiring an additional 129 shares during the period. 14.44% of the stock is currently owned by institutional investors.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with our FREE daily email newsletter.